Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus

Back to Jobs

Results expected in first half of 2020 SAN DIEGO , April 11, 2019 (GLOBE NEWSWIRE) — Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-313, a

Apply Now